PMID- 17349874
OWN - NLM
STAT- MEDLINE
DCOM- 20070606
LR  - 20111117
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 68
IP  - 3
DP  - 2007 Mar
TI  - Human leukocyte antigen class II alleles and risk of cervical cancer in China.
PG  - 192-200
AB  - Human leukocyte antigen (HLA) class II alleles have been associated with an 
      increased or decreased risk of developing cervical cancer through infection with 
      oncogenic forms of human papillomavirus (HPV). To verify whether HLA class II 
      allelic polymorphism is related to cervical cancer in China, 133 cervical cancers 
      and 98 healthy controls were analyzed for HLA typing. Our results showed that 
      DPB1*1301 allele frequency was significantly higher in the cervical cancers 
      compared with healthy controls (OR, 3.793; p = 0.002; Pc = 0.04). A significant 
      relationship was found between DRB1*150101-DQB1*0602 haplotype (OR, 0.180; p < 
      0.0001; Pc < 0.003), DRB1*070101-DQB1*0201 haplotype (OR, 0.110; p = 0.001; Pc = 
      0.03), and decreased risk for cervical cancer. Similar tendencies were observed 
      for DRB1*150101-DQB1*0602 haplotype with HPV16 positive cervical cancers (OR, 
      0.182; p = 0.001; Pc = 0.021), and for DRB1*070101-DQB1*0201 haplotype (OR, 
      0.144; p =0.003; Pc = 0.063). These results indicate that HLA-DPB1*1301 may 
      confer susceptibility to cervical cancer, and the haplotypes 
      DRB1*150101-DQB1*0602 and DRB1*070101-DQB1*0201 may contribute to the resistance 
      to the development of cervical cancer among Chinese women. The study suggests 
      that specific HLA class II alleles and haplotypes may influence the immune 
      response to specific HPV-encoded epitopes and affect the risk of cervical cancer 
      in a Chinese population from an area with a high incidence of this neoplasia.
FAU - Wu, Yuping
AU  - Wu Y
AD  - State Key Laboratory of Biocontrol, Department of Biochemistry, School of Life 
      Sciences, Sun Yat-Sen (Zhongshan) University, Guangzhou, P.R. China.
FAU - Liu, Benrong
AU  - Liu B
FAU - Lin, Wenzhi
AU  - Lin W
FAU - Xu, Yunping
AU  - Xu Y
FAU - Li, Longyu
AU  - Li L
FAU - Zhang, Yanling
AU  - Zhang Y
FAU - Chen, Shangwu
AU  - Chen S
FAU - Lin, Zhongqiu
AU  - Lin Z
FAU - Xu, Anlong
AU  - Xu A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060807
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (DNA, Viral)
RN  - 0 (HLA-D Antigens)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (HLA-DPB1 antigen)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - Alleles
MH  - Alphapapillomavirus/isolation & purification
MH  - Amino Acid Sequence
MH  - Carcinoma, Squamous Cell/*epidemiology/genetics/immunology
MH  - DNA, Viral/analysis
MH  - Exons/genetics
MH  - Female
MH  - Gene Frequency
MH  - *Genes, MHC Class II
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA-D Antigens/*genetics
MH  - HLA-DP Antigens/genetics
MH  - HLA-DP beta-Chains
MH  - HLA-DQ Antigens/genetics
MH  - HLA-DQ beta-Chains
MH  - HLA-DR Antigens/genetics
MH  - HLA-DRB1 Chains
MH  - Human papillomavirus 16/isolation & purification
MH  - Humans
MH  - Immunity, Innate
MH  - Incidence
MH  - Papillomavirus Infections/epidemiology
MH  - Polymorphism, Genetic
MH  - Risk
MH  - Tumor Virus Infections/epidemiology
MH  - Uterine Cervical Neoplasms/*epidemiology/genetics/immunology
EDAT- 2007/03/14 09:00
MHDA- 2007/06/07 09:00
CRDT- 2007/03/14 09:00
PHST- 2006/05/09 00:00 [received]
PHST- 2006/06/27 00:00 [revised]
PHST- 2006/07/11 00:00 [accepted]
PHST- 2007/03/14 09:00 [pubmed]
PHST- 2007/06/07 09:00 [medline]
PHST- 2007/03/14 09:00 [entrez]
AID - S0198-8859(06)00170-4 [pii]
AID - 10.1016/j.humimm.2006.07.005 [doi]
PST - ppublish
SO  - Hum Immunol. 2007 Mar;68(3):192-200. doi: 10.1016/j.humimm.2006.07.005. Epub 2006 
      Aug 7.